雷珠单抗不同治疗方案治疗视网膜分支静脉阻塞继发黄斑水肿的疗效比较  

Comparison of the Efficacy of Different Treatment Regimens of Ranibi⁃zumab in the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion

作　　者：文美丹 何小娟 罗海燕[1] 郝晓辉 杨帆[1] WEN Meidan;HE Xiaojuan;LUO Haiyan;HAO Xiaohui;YANG Fan(Department of Ophthalmology,Nanxishan Hospital of Guangxi Zhuang Autonomous Region,Guilin,Guangxi Zhuang Autonomous Region,541002 China)

机构地区：[1]广西壮族自治区南溪山医院眼科,广西桂林541002

出　　处：《系统医学》2024年第5期1-4,8,共5页Systems Medicine

基　　金：广西壮族自治区卫生健康委员会自筹科研课题(Z20201408);广西壮族自治区卫生健康委员会自筹科研课题(Z20190734);广西壮族自治区南溪山医院院级科研课题(NY202003)。

摘　　要：目的观察雷珠单抗不同治疗方案治疗视网膜分支静脉阻塞继发黄斑水肿的临床效果。方法选取2020年7月—2022年1月广西壮族自治区南溪山医院收治的60例(60眼)视网膜分支静脉阻塞相关黄斑水肿患者为研究对象。采用随机数表法将其分为两组,每组30例。1+按需治疗(Prore Nata,PRN)组:雷珠单抗初始1针玻璃体腔注药后改为按需注药。3+RPN组:雷珠单抗璃体腔内初始3次注射,1次/月,连续3个月负荷治疗后改为按需注药。观察两组首次注射后1、3、6、12个月的最佳矫正视力及黄斑中心凹视网膜厚度变化情况,以及1年中两组平均注射次数及黄斑水肿复发率的差异。结果两组治疗前、治疗后1、3、6、12个月的最佳矫正视力、黄斑中心凹视网膜厚度水平比较,差异无统计学意义(P均>0.05)。1年内,1+PRN组的雷珠单抗平均注射次数明显少于3+PRN组,差异有统计学意义(t=4.017,P<0.001)。1年内,3+PRN组复发率略低于1+PRN组,但差异无统计学意义(P>0.05)。结论与1+PRN方案相比,3+PRN方案在临床应用中并没有带来更好的功能结果或更低的治疗需求。Objective To observe the clinical effects of different treatment regimens of ranibizumab in the treatment of macular edema secondary to branch retinal vein occlusion.Methods 60 cases(60 eyes)of macular edema associated with branch retinal vein occlusion from July 2020 to January 2022 admitted to the Nanxishan Hospital of Guangxi Zhuang Autonomous Region were selected as the study objects.They were divided into two groups using the random⁃ized numeric table method.1+Prore Nata(PRN)group:ranibizumab was given as an initial vitreous injection and then changed to an on-demand injection.3+RPN group:ranibizumab was injected intravitreal initially 3 times,once a month,and then changed to as-needed injection after 3 consecutive months of sub-loading treatment.The changes in best-corrected visual acuity and retinal thickness in the macular center recess at 1,3,6 and 12 months after the first injection were observed in the two groups,as well as the differences in the mean number of injections and the recur⁃rence rate of macular edema in the two groups over 1 year.Results The differences in the levels of best-corrected visual acuity and macular center recess retinal thickness before treatment and at 1,3,6,and 12 months after treatment between the two groups were not statistically significant(all P>0.05).Within 1 year,the mean number of ranibizumab injections in the 1+PRN group was significantly less than that in the 3+PRN group,and the difference was statistically significant(t=4.017,P<0.001).Within 1 year,the recurrence rate was lower of the 3+PRN group than that of the 1+PRN group,but the difference was not statistically significant(P>0.05).Conclusion Compared with the 1+PRN regi⁃men,the 3+PRN regimen did not lead to better functional outcomes or lower treatment needs in clinical applications.

关 键 词：雷珠单抗 视网膜分支静脉阻塞 黄斑水肿 

分 类 号：R774.6[医药卫生—眼科]